Even as a trial over alleged antitrust activity over drug patents gears up for March, drug makers AstraZeneca, Ranbaxy Pharmaceuticals, Teva Pharmaceuticals and Dr. Reddy’s Laboratories are hoping that the First Circuit will unwind a district judge’s decision to certify a class action of drug purchasers.
The plaintiffs are challenging the patent settlements between AstraZeneca and the three generic drug makers over the gastrointestinal drug Nexium on the grounds that the accords delayed the entry of generic versions of the drug until May of this year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
